Biswanath De
Procter & Gamble
120 Papers
1.5K Citations
Biswanath De is an academic researcher from Procter & Gamble. The author has contributed to research in topics: Matrix metalloproteinase inhibitor & Aryl. The author has an hindex of 29, co-authored 120 publications.
Chat about Author
Papers
Angiotensin ii receptor antagonists
Martin Winn,Biswanath De,Thomas M. Zydowsky,Daniel J. Kerkman,John F. DeBernardis,Saul H. Rosenberg,Kazumi Shiosaki,Fatima Z. Basha,Kenneth P. Spina,Thomas W. von Geldern,Steven A. Boyd,Diane M. Yamamoto,Anthony K. L. Fung +12 more
- 24 Feb 1993
TL;DR: Functional studies with AT1-antagonists indicate that Ang II antagonism at the receptor level can be rather complex, and experimental data suggests that not only are receptor binding kinetics involved, but also that additional binding sites, and possibly even AT1 subtypes, are involved.
196
Design and synthesis of piperazine – based matrix metalloproteinase inhibitors
Cheng Menyan,Biswanath De,Stanislaw Pikul,Neil Gregory Almstead,Michael George Natchus,M.V. Anastasio,Sara Johnson Mcphail,Catherine E. Snider,Y.O. Taiwo,Longyin Chen,C. M. Dunaway,Fei Gu,Martin E. Dowty,Glen E. Mieling,Michael J. Janusz,S. Wang-Weigand +15 more
TL;DR: A new generation of cyclic matrix metalloproteinase (MMP) inhibitors derived from dl-piperazinecarboxylic acid has been described, with unique combination of all three elements producing inhibitor 20 with high affinity for MMPs 1, 3, 9, and 13.
100
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
Neil Gregory Almstead,Rimma Sandler Bradley,Stanislaw Pikul,Biswanath De,Michael George Natchus,Y.O. Taiwo,Fei Gu,Lisa E. Williams,Barbara A. Hynd,Michael J. Janusz,C. M. Dunaway,Glen E. Mieling +11 more
TL;DR: The synthesis and enzyme inhibition data for a series of thiazine- and thiazepine-based matrix metalloproteinase (MMP) inhibitors are described and the most potent series of inhibitors was obtained by modification of the amino acid D-penicillamine.
88
Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
Michael P. Clark,Kelly M. George,Roger G. Bookland,Jack J. Chen,Steven K. Laughlin,Kumar D. Thakur,Wenlin Lee,Jan Richard Davis,Ed J. Cabrera,Todd A. Brugel,John C. VanRens,Matthew J. Laufersweiler,Jennifer A. Maier,Mark Sabat,Adam Golebiowski,Vijay Easwaran,Mark E. Webster,Biswanath De,George Zhang +18 more
TL;DR: A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described and many of these inhibitors showed low nanomolar activity against Jak-3.
80
Design and Synthesis of Phosphinamide-Based Hydroxamic Acids as Inhibitors of Matrix Metalloproteinases
Stanislaw Pikul,Kelly McDow Dunham,Neil Gregory Almstead,Biswanath De,Michael George Natchus,Melanie V. Anastasio,Sara Johnson Mcphail,Catherine E. Snider,Yetunde Olabisi Taiwo,Longyin Chen,C. Michelle Dunaway,and Fei Gu,Glen E. Mieling +12 more
TL;DR: A new series of hydroxamic acid-based matrix metalloproteinase (MMP) inhibitors containing a unique phosphinamide motif derived from D-amino acid was designed, synthesized, and tested for enzyme inhibition.
76